Want to cut your energy bills? Here’s how five experts are doing it 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
WALTHAM, Mass., March 31, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 09:20 AM EDT at the Westin Grand Central Hotel in New York, NY.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
